Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole
Mem. Inst. Oswaldo Cruz
; 111(3): 218-221, Mar. 2016. tab, graf
Article
in English
| LILACS
| ID: lil-777373
Responsible library:
BR1.1
ABSTRACT
Pharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in children in all stages, but it is controversial in chronically infected adults. We report the pharmacokinetics and pharmacodynamics in six adult patients with Chagas disease treated with the new BNZ formulation (ABARAX®) in doses between 2.5-5.5 mg/Kg/day. All but one patient had plasmatic BNZ concentrations within the expected range. All patients finalised treatment with nondetectable Trypanosoma cruziquantitative polymerase chain reaction, which remained nondetectable at the six month follow-up. Our data suggests parasitological responses with the new BNZ and supports the hypothesis that treatment protocols with lower BNZ doses may be effective.
Full text:
Available
Collection:
International databases
Health context:
Neglected Diseases
Health problem:
Chagas Disease
/
Neglected Diseases
Database:
LILACS
Main subject:
Trypanocidal Agents
/
Trypanosoma cruzi
/
Chagas Disease
/
Nitroimidazoles
Type of study:
Practice guideline
/
Observational study
/
Prognostic study
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
English
Journal:
Mem. Inst. Oswaldo Cruz
Journal subject:
Tropical Medicine
/
Parasitology
Year:
2016
Document type:
Article
Affiliation country:
Argentina
Institution/Affiliation country:
Instituto Nacional de Parasitología Dr M Fatala Chabén/AR